Castle | $1,000,000 | (Jun 27, 2025)
Handspring Health | $12,000,000 | (Jun 27, 2025)
DejaBlue | $8,000,000 | (Jun 27, 2025)
Certified by Founder
Lodge
Exeliom Biosciences
start up
France
- Dijon, Bourgogne-Franche-Comté
- 21/07/2023
- Series A
- $8,898,320
At Exeliom Biosciences, we develop single bacterial strain drug candidates to deliver first-in-class microbiome-based therapeutics (also known as Live Biotherapeutics) for the treatment of immune-mediated diseases, with specific focus on inflammatory bowel diseases (IBD), and Crohn’s Disease as a first indication
- Industry Pharmaceutical Manufacturing
- Website https://www.exeliombio.com/
- LinkedIn https://www.linkedin.com/company/nextbiotix/
Related People
Benjamin HadidaFounder
France -
Paris, Île-de-France
Biotech company builder and new therapeutic class explorer
Certify | $40,000,000 | (Jun 27, 2025)
Tacta Systems, Inc. | $7,000,000 | (Jun 27, 2025)
Antler Bio | $4,212,546 | (Jun 27, 2025)
Raphe mPhibr | $100,000,000 | (Jun 27, 2025)
DataBahn.ai | $17,000,000 | (Jun 27, 2025)
Klutch AI | $8,000,000 | (Jun 27, 2025)
Niural | $31,000,000 | (Jun 27, 2025)
Jarsy Inc | $5,000,000 | (Jun 27, 2025)
Spekter Games | $5,000,000 | (Jun 27, 2025)